Impact Biomedical (IBO) Revenue (2022 - 2026)

Impact Biomedical (IBO) has reported Revenue for 3 consecutive years, with $3000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 57.14% year-over-year to $3000.0; the trailing twelve-month figure through Jun 2026 stood at $35000.0 (down 38.6% YoY), and the FY2022 full-year result was $50000.0, changed N/A from the prior year.
• Revenue retreated to $3000.0 in Q2 2026 per IBO's latest filing, from $7000.0 in the prior quarter.
• Across five years, Revenue topped out at $50000.0 in Q2 2022 and bottomed at $3000.0 in Q2 2026.
• Historically, Revenue has averaged $17000.0 across 3 years, with a median of $7000.0 in 2025.
• The widest YoY moves for Revenue: up 57.14% in 2026, down 57.14% in 2026.
• Over 3 years, Revenue stood at $50000.0 in 2022, then tumbled by 64.0% to $18000.0 in 2025, then slumped by 83.33% to $3000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $3000.0, $7000.0, and $18000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.